Cereset Research for Caregivers
Wake Forest University Health Sciences · with Memory Counseling Program general fund, Heidi Munger-Clary, MD · NCT05209438
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 20
- US sites recruiting
- 1
- Study start
- June 16, 2022
- Record last updated
- June 1, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Caregivers experience high levels of prolonged stress that can lead to chronic problems with health, including increased risk of cardiovascular disease that is linked to autonomic dysregulation. Heart rate variability (HRV), measures of autonomic cardiovascular regulation, is decreased (worse) in caregivers. Autonomic function is linked to lateralization in the brain, and emerging neuromodulation methods that target lateralized signals in the brain, like Cereset (CR), may be able to improve heart rate variability. Therefore, this pilot study aims to test whether CR can improve HRV in caregivers of a person living with dementia experiencing stress, anxiety, or insomnia, as well as improve self-report measures of stress, sleep and caregiver burden.
Being studied: Cereset Research
Conditions: Caregivers
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participants must provide caregiving at least 10 hours per week. This includes all types of caregiving
- participants must be willing to provide informed consent
- participants must be able to comply with basic instructions
- participants must be able to sit comfortably for up to 90 minutes, and attend up to three 60-minute intervention sessions each week during the 4-week intervention period
- participants must self report experiencing symptoms of stress, anxiety, or insomnia and meet threshold scores on one or more self-report inventories of these symptoms (Insomnia Severity Index (ISI, ≥ 8), the Perceived Stress Index (PSS, ≥ 14), or the Generalized Anxiety Disorder 7-item (GAD-7, ≥ 5) scale)
Exclusion criteria
- participants providing less than 10 hours a week of care to a person
- participants who are unable or unwilling to attend intervention sessions during the planned study period
- participants who are unable or unwilling to provide consent
- participants who are not exhibiting symptoms of stress, anxiety or insomnia
- participants with hearing impairment severe enough that they cannot perceive tones through ear buds
- participants with known seizure disorder, or suicidal thoughts within the last 3 months
- participants who respond positively to a question about risk for suicide within the last 3 months will be excluded and receive a behavioral health resource list
- participants weighing more than 400 pounds (the weight limit of the chair used during intervention)
- participants currently enrolled in another intervention study
- prior use (past 3 years) of the technology being tested
- prior use of neuromodulation, neurostimulation, deep brain stimulation, neurofeedback, biofeedback, alpha stim, Eye Movement Desensitization and Reprocessing (EMDR),or electroconvulsive therapy within the last month
- Pace makers and beta blockers that affect the assessment of heart rate variability will also be exclusionary
- participants taking Medications that may affect the assessment of heart rate variability (beta blockers.
Recruiting US locations
Wake Forest University Health Sciences
Winston-Salem, NC 27157
Site contact: Kenzie Brown · 336-716-9447 · BBRP@wakehealth.edu
Study contacts (from the official record)
- Kenzie Brown · 336-716-9447 · BBRP@wakehealth.edu
- Charles Tegeler, MD · 336-716-7651 · Charles.Tegeler@wfusm.edu
Similar studies in North Carolina
All sleep studies in North Carolina →- RecruitingPhase 2/Phase 3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.
- Location
- Denver, NC + 32 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Takeda
- Location
- Denver, NC + 24 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH
Jazz Pharmaceuticals
- Location
- Denver, NC + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Charlotte, NC + 21 other US sites
- Eligibility basics
- Ages 18–70